诺和诺德Novo Nisk（NVO）2025年第一季度财务业绩公告「NYSE」（英文版）（36页）.pdf

1、Financial report for the period 1 January 2025 to 31 March 20257 May 2025 Novo Nordisks sales increased by 19%in Danish kroner and by 18%at constant exchange rates to DKK 78.1 billion in the first three months of 2025 Operating profit increased by 22%in Danish kroner and by 20%at constant exchange r

2、ates(CER)to DKK 38.8 billion.Sales in US Operations increased by 20%in Danish kroner(17%at CER).Sales in International Operations increased by 18%in Danish kroner(19%at CER).Sales within Diabetes and Obesity care increased by 21%in Danish kroner to DKK 73.5 billion(19%at CER),mainly driven by Obesit

3、y care growth of 67%in Danish kroner to DKK 18.4 billion(65%at CER)and GLP-1 diabetes sales growing 13%in Danish kroner(11%at CER)and.Rare disease sales increased by 5%measured in Danish kroner(3%at CER).Within R&D,Novo Nordisk completed the REDEFINE 2 trial,where CagriSema demonstrated superior wei

4、ght loss of 15.7%in adults with obesity or overweight and type 2 diabetes.Novo Nordisk still expects to file for the first regulatory approval of CagriSema during the first quarter of 2026.Also within R&D,oral semaglutide 25 mg in obesity was submitted for regulatory review to the US FDA.In addition

5、,once-weekly semaglutide 2.4 mg in MASH was submitted for regulatory approval in both the EU and US,and granted priority review in the US.For the 2025 outlook,sales growth is now expected to be 13-21%at CER,and operating profit growth is now expected to be 16-24%at CER.Sales and operating profit gro

6、wth reported in Danish kroner is now expected to be 3 and 5 percentage points lower than at CER,respectively.The updated sales outlook reflects lower-than-planned penetration of branded GLP-1 treatments in the US,impacted by compounded GLP-1s.Novo Nordisk is focused on preventing unlawful compoundin